利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

57 条记录 (耗时 0.052 秒)

    Combination for treatment of proliferative diseases
    3.
    发明授权
    Combination for treatment of proliferative diseases 失效
    用于治疗增殖性疾病的组合

    公开(公告)号：US5744460A

    公开(公告)日：1998-04-28

    申请号：US612775

    申请日：1996-03-07

    申请人： Marcel Muller ,  Thomas Geiger ,  Karl-Heinz Altmann ,  Doriano Fabbro ,  Nicholas M. Dean ,  Brett Monia ,  Clarence Frank Bennett

    发明人： Marcel Muller ,  Thomas Geiger ,  Karl-Heinz Altmann ,  Doriano Fabbro ,  Nicholas M. Dean ,  Brett Monia ,  Clarence Frank Bennett

    IPC分类号： A61K45/06 ,  A61K31/44 ,  A61K31/445 ,  A61K31/505 ,  A61K31/53 ,  A61K31/70 ,  A61K48/00 ,  C07H21/04

    CPC分类号： A61K31/70 ,  A61K45/06

    摘要： The invention relates to combinations of PKC-targeted (especially PKC-.alpha.-targeted) deoxyribo- and ribo-oligonucleotides and derivatives thereof with other chemotherapeutic compounds, as well as to pharmaceutical preparations and/or therapies, in relation to disease states which respond to such oligonucleotides or oligonucleotide derivatives, especially to to modulation of the activity of a regulatory protein. In particular, the invention relates to products or combinations comprising antisense oligonucleotides or oligonucleotide derivatives targeted to nucleic acids encoding human PKC and other (preferably standard) chemotherapeutics, either in fixed combination or for chronologically staggered or simultaneous administration, and the combined use of both classes of compounds, either in fixed combination or for chronologically staggered or simultaneous administration, for the treatment of proliferative diseases, especially tumor diseases, that can be treated by inhibition of PKC activity, that is, where the antisense oligonucleotides or oligonucleotide derivatives are targeted to nucleic acids encoding the regulatory protein PKC or active mutated derivatives thereof.

    摘要翻译： 本发明涉及PKC靶向（特别是PKC-α靶向的）脱氧核糖核苷酸和核糖寡核苷酸及其衍生物与其它化学治疗化合物的组合，以及关于响应于所述药物的疾病状态的药物制剂和/或治疗 这样的寡核苷酸或寡核苷酸衍生物，特别是调节调节蛋白的活性。 特别地，本发明涉及包含针对编码人PKC的核酸的反义寡核苷酸或寡核苷酸衍生物或其它（优选标准的）化学治疗剂的产品或组合，其以固定组合或按时间顺序交错或同时施用，以及两类的组合使用 的化合物，以固定组合或按时间顺序交错或同时给药，用于治疗可通过抑制PKC活性治疗的增殖性疾病，特别是肿瘤疾病，即反义寡核苷酸或寡核苷酸衍生物靶向核酸 编码调节蛋白PKC的酸或其活性突变衍生物。

    Antisense oligonucleotide compositions and methods for the modulation of JNK proteins
    6.
    发明授权
    Antisense oligonucleotide compositions and methods for the modulation of JNK proteins 失效
    反义寡核苷酸组合物和调节JNK蛋白的方法

    公开(公告)号：US06809193B2

    公开(公告)日：2004-10-26

    申请号：US09774809

    申请日：2001-01-31

    申请人： Robert McKay ,  Nicholas M. Dean ,  Brett P. Monia ,  Pamela Nero ,  William A. Gaarde

    发明人： Robert McKay ,  Nicholas M. Dean ,  Brett P. Monia ,  Pamela Nero ,  William A. Gaarde

    IPC分类号： C12N1585

    CPC分类号： C12N15/1137 ,  A61K38/00 ,  C07H21/00 ,  C12N2310/315 ,  C12N2310/321 ,  C12N2310/334 ,  C12N2310/3341 ,  C12N2310/341 ,  C12N2310/346 ,  C12N2310/3515 ,  C12Q1/6886 ,  C12Q2600/158 ,  C12N2310/3525

    摘要： Compositions and methods for the treatment and diagnosis of diseases or disorders amenable to treatment through modulation of expression of a gene encoding a Jun N-terminal kinase (JNK protein) are provided. Oligonucleotide are herein provided which are specifically hybridizable with nucleic acids encoding JNK1, JNK2 and JNK3, as well as other JNK proteins and specific isoforms thereof. Methods of treating animals suffering from diseases or disorders amenable to therapeutic intervention by modulating the expression of one or more JNK proteins with such oligonucleotide are also provided. Methods for the treatment and diagnosis of diseases or disorders associated with aberrant expression of one or more JNK proteins are also provided. Methods for inducing apoptosis and for treating diseases or conditions associated with a reduction in apoptosis are also provided.

    摘要翻译： 提供了通过调节编码JunN末端激酶（JNK蛋白）的基因的表达进行治疗的疾病或病症的治疗和诊断的组合物和方法。 本文提供了与编码JNK1，JNK2和JNK3的核酸以及其它JNK蛋白及其特异性同种型特异性杂交的寡核苷酸。 还提供了通过用这种寡核苷酸调节一种或多种JNK蛋白质的表达来治疗患有治疗性干预的疾病或障碍的动物的方法。 还提供了用于治疗和诊断与一种或多种JNK蛋白异常表达相关的疾病或病症的方法。 还提供了用于诱导凋亡和用于治疗与凋亡降低相关的疾病或病症的方法。

    Antisense inhibition of Fas mediated signaling
    8.
    发明授权
    Antisense inhibition of Fas mediated signaling 失效
    反义抑制Fas介导的信号传导

    公开(公告)号：US06204055B1

    公开(公告)日：2001-03-20

    申请号：US09290640

    申请日：1999-04-12

    申请人： Nicholas M. Dean ,  Eric G. Marcusson

    发明人： Nicholas M. Dean ,  Eric G. Marcusson

    IPC分类号： C07H2104

    CPC分类号： C12N15/1138 ,  A61K38/00 ,  C12N2310/315 ,  C12N2310/321 ,  C12N2310/3341 ,  C12N2310/341 ,  C12N2310/346 ,  Y02P20/582 ,  C12N2310/3525

    摘要： Compounds, compositions and methods are provided for inhibiting Fas mediated signaling. The compositions comprise antisense compounds targeted to nucleic acids encoding Fas, FasL and Fap-1. Methods of using these antisense compounds for inhibition of Fas, FasL and Fap-1 expression and for treatment of diseases, particularly autoimmune and inflammatory diseases and cancers, associated with overexpression or constitutive activation of Fas, FasL or Fap-1 are provided.

    摘要翻译： 提供化合物，组合物和方法用于抑制Fas介导的信号传导。 组合物包含靶向编码Fas，FasL和Fap-1的核酸的反义化合物。 提供了使用这些反义化合物抑制Fas，FasL和Fap-1表达以及治疗与Fas，FasL或Fap-1的过度表达或组成型激活相关的疾病，特别是自身免疫性和炎性疾病和癌症的方法。

    Oligonucleotides for enhanced modulation of protein kinase C expression
    9.
    发明授权
    Oligonucleotides for enhanced modulation of protein kinase C expression 失效
    用于增强蛋白激酶C表达调节的寡核苷酸

    公开(公告)号：US6117847A

    公开(公告)日：2000-09-12

    申请号：US94714

    申请日：1998-06-15

    申请人： C. Frank Bennett ,  Nicholas M. Dean

    发明人： C. Frank Bennett ,  Nicholas M. Dean

    IPC分类号： A61K38/00 ,  C12N9/12 ,  C12N15/113 ,  C12Q1/68 ,  A61K31/70 ,  C07H21/00

    CPC分类号： C12N15/1137 ,  C12N9/12 ,  C12Q1/6876 ,  C12Q1/6883 ,  A61K38/00 ,  C12N2310/315 ,  C12N2310/321 ,  C12N2310/3341 ,  C12N2310/341 ,  C12N2310/346 ,  C12Q2600/158

    摘要： Compositions and methods are provided for modulating the expression of protein kinase C. Oligonucleotides are provided which are targeted to nucleic acids encoding PKC. The oligonucleotides are from 5 to 50 nucleotides in length and in one referred embodiment are from 12 to 18 nucleotides in length. The oligonucleotides may be chimeric oligonucleotides and in a preferred embodiment comprise at least one 2'-O-methoxyethyl modification. Pharmaceutical compositions comprising the oligonucleotides of the invention are also provided. Methods of inhibiting protein kinase C expression and methods of treating conditions associated with expression of protein kinase C using oligonucleotides of the invention are disclosed.

    摘要翻译： 提供组合物和方法用于调节蛋白激酶C的表达。提供靶向编码PKC的核酸的寡核苷酸。 寡核苷酸长度为5至50个核苷酸，并且在一个所提及的实施方案中，长度为12至18个核苷酸。 寡核苷酸可以是嵌合寡核苷酸，并且在优选的实施方案中包含至少一个2'-O-甲氧基乙基修饰。 还提供了包含本发明的寡核苷酸的药物组合物。 公开了使用本发明的寡核苷酸抑制蛋白激酶C表达的方法和与蛋白激酶C的表达相关的病症的治疗方法。